SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: NotAsBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 2/20/2017 5:15:29 PM - Followers: 707 - Board type: Free - Posts Today: 78

Cellceutix Corporation (CTIX)
 

 

http://cellceutix.com/
 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com
 
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Brilacidin is also being evaluated in a Phase 2 Proof-of-Concept trial as a novel treatment for Ulcerative Proctitis. Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com. 

Management:  http://cellceutix.com/team/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/

 

FDA Designations:
 


Upcoming Milestones:
 


Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx

 
SEC Filings (CIK:0001355250):  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275

 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  info@cellceutix.com

Following is a WEEKLY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CTIX News: Current Report Filing (8-k) 02/16/2017 07:01:38 AM
CTIX News: Quarterly Report (10-q) 02/09/2017 04:04:17 PM
CTIX News: Current Report Filing (8-k) 02/09/2017 09:39:24 AM
CTIX News: Amended Statement of Ownership (sc 13g/a) 01/04/2017 03:58:28 PM
CTIX News: Current Report Filing (8-k) 11/15/2016 06:25:29 AM
PostSubject
#172374  Sticky Note PIPELINE STAGES, FDA DESIGNATIONS, UPDATE BooDog 02/17/17 08:05:49 AM
#172192  Sticky Note $CTIX - Cellceutix Reports on Q2 Fiscal 2017, KarinCA 02/16/17 07:39:33 AM
#172129  Sticky Note It seems like Dr Bertolino made reference to KarinCA 02/15/17 03:24:47 PM
#169697  Sticky Note Absolute proof that AF's intent was and is georgejjl 01/25/17 08:29:12 PM
#165552  Sticky Note B-UP Due Diligence sox040713 12/09/16 12:17:52 PM
#165491  Sticky Note New Oral Psoriasis Drug Tops Cellceutix Catalysts $CTIX http://www.seekingalpha. Matagordaville 12/08/16 04:55:12 PM
#172714   $2 with excellent results only. MrW 02/20/17 05:15:29 PM
#172713   Maybe bunny is AF? septmike09 02/20/17 04:53:17 PM
#172712   Bunny Have you read anything on Central Banks to Echo20 02/20/17 04:12:40 PM
#172710   If February had 30 days he be dead on:) kfcyahoo 02/20/17 02:59:41 PM
#172709   So the company raising money to fund 4 eventhelosers 02/20/17 02:58:54 PM
#172704   WIth only 6 trading days left, those are zandant 02/20/17 02:05:05 PM
#172703   That info, while "news," summarizes the company's January zandant 02/20/17 02:02:17 PM
#172700   NEWS!!!!!!!!!!!! http://www.cellceutix.com/new-blog/2017/2/2/endoscopic-remission-in-the-tre runninggirl2017 02/20/17 01:47:59 PM
#172698   No problem, I don't know why 'they' (the TheBunny 02/20/17 01:41:19 PM
#172697   Congrats! Do you think your $1 prediction would sox040713 02/20/17 01:40:12 PM
#172695   I'll believe George before therabbit! cabel 02/20/17 01:38:13 PM
#172694   George is the only reason I'm snooping around akamaii 02/20/17 01:32:44 PM
#172693   George. You are a true believer as I groton68 02/20/17 01:28:25 PM
#172692   It has been duly noted. cybermich 02/20/17 01:10:24 PM
#172691   I've changed my mind...P will be a failure! runninggirl2017 02/20/17 01:06:02 PM
#172690   Yeah all sellers are dumping free shares. LMAO septmike09 02/20/17 12:56:56 PM
#172689   you mean as jav0033 runninggirl2016 02/20/17 12:51:30 PM
#172688   sorry that there are more sellers than buyers....any untohim 02/20/17 12:51:17 PM
#172687   If it happens within the next 6 days, choctaw 02/20/17 12:45:32 PM
#172686   If it happens in the next 6 days, jav0033 02/20/17 12:43:23 PM
#172685   Expect CTIX to be trading between $3 and georgejjl 02/20/17 12:35:23 PM
#172684   Cellceutix is consulting with a world renowned expert georgejjl 02/20/17 12:33:22 PM
#172683   paraphrasing, you premised your statement that there are untohim 02/20/17 12:33:18 PM
#172682   So jeorge do you intend on revising your JTORENCE 02/20/17 12:27:17 PM
#172681   Expect Better Than Outstanding Results from the current georgejjl 02/20/17 12:10:22 PM
#172680   “To date, the trial has exceeded our expectations georgejjl 02/20/17 12:07:17 PM
#172679   IMHO, the test results need to be Outstanding TheBunny 02/20/17 12:00:32 PM
#172678   Within just 2 weeks Brilacidin—Inflammatory Bowel Diseases Ulcerative georgejjl 02/20/17 11:59:17 AM
#172677   kind of a short sighted view.. cybermich 02/20/17 11:58:07 AM
#172676   You must be one of those self proclaimed cybermich 02/20/17 11:56:24 AM
#172675   Assuming the results are positive from the upcoming septmike09 02/20/17 11:54:19 AM
#172674   What will the results be ? How will TheBunny 02/20/17 11:49:55 AM
#172673   So why not answer the question? Do you septmike09 02/20/17 11:33:41 AM
#172671   RG Especially if nontoxic. Echo20 Echo20 02/20/17 11:29:51 AM
#172670   I won't even be here in five years. septmike09 02/20/17 11:29:11 AM
#172669   Keep telling how great Leo is doing, he TheBunny 02/20/17 11:27:37 AM
#172667   They already know that Prurisol is working. 57.1% georgejjl 02/20/17 11:08:49 AM
#172666   shouldn't take long at all to see if runninggirl2016 02/20/17 11:03:56 AM
#172665   So then you think the stock will continue septmike09 02/20/17 11:01:11 AM
#172664   Can you imagine cancer patients taking Kevetrin pills georgejjl 02/20/17 10:47:11 AM
#172663   CTIX is moving forward on many fronts! Thanks EasyRider 02/20/17 10:46:53 AM
#172662   Excellent. 3 weeks of 3xs dosing. DaubersUP 02/20/17 10:39:05 AM
#172661   Trial #8 is now recruiting patients. Leo sox040713 02/20/17 10:21:17 AM
#172660   I agree CTIX has more potential.....once we get stevo99 02/20/17 10:01:38 AM
#172659   Yep. Exactly why I said Leo might runninggirl2017 02/20/17 09:47:32 AM
#172658   As shown, it was momentary spike. That's All. TheBunny 02/20/17 09:45:33 AM
#172657   K for Ovarian status is now RECRUITING! runninggirl2016 02/20/17 09:36:01 AM
#172656   runninggirl I agree. georgejjl 02/20/17 09:35:46 AM
#172655   If P proves to be as good as runninggirl2016 02/20/17 09:31:41 AM
#172654   If CTIX wants to be the next Regeneron stevo99 02/20/17 09:31:30 AM
PostSubject